All these findings point to primary (SPG7) or secondary (SPG11) mitochondrial dysfunction as a major cause of axonal vulnerability in HSP, indicating that treatments focusing on mitochondrial stress may be advantageous for different subtypes. The gene discussed is SPG11; the disease is hereditary spastic paraplegia.